BFA
IMNP

BlackRock Fund Advisors’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

BlackRock Fund Advisors’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2K Buy
447
+108
+32% +$444 ﹤0.01% 4170
2016
Q3 		$2K Buy
339
+38
+13% +$281 ﹤0.01% 4192
2016
Q2 		$2K Sell
301
-3,105
-91% -$24.2K ﹤0.01% 4247
2016
Q1 		$29K Sell
3,406
-253
-7% -$2.6K ﹤0.01% 3869
2015
Q4 		$54K Buy
+3,659
New +$76.9K ﹤0.01% 3857

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EEG
E.E. Geduld $178M AUM 29.34% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

BlackRock Fund Advisors's IMNP Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Immune Pharmaceuticals Inc. (IMNP) stake by 32% in Q4 2016, buying an estimated $444 and bringing the position to 447 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.

BlackRock Fund Advisors first reported a position in IMNP in Q4 2015 and has held it in 5 quarters since. The position peaked at $54K in Q4 2015. 14 funds tracked by Wall St. Rank hold IMNP as of Q4 2016.

  • BlackRock Fund Advisors held 447 shares of Immune Pharmaceuticals Inc. worth $2K as of Q4 2016.
  • BlackRock Fund Advisors bought 108 Immune Pharmaceuticals Inc. shares in Q4 2016, an estimated $444.
  • Immune Pharmaceuticals Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4170 holding.
  • BlackRock Fund Advisors first reported a position in Immune Pharmaceuticals Inc. in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Fund Advisors's Immune Pharmaceuticals Inc. position peaked at $54K in Q4 2015.
  • 14 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.